The estimates from the U.S. cross-sectional study are about 45 new cases per 100,000 person year or approximately 7 per 1000 new cases of myositis, inclusion body per year and per 100,000 person year in U.S adults.
No single medication has been identified as a standard treatment. Anti-mitogen or immunosuppressant medications may be considered when myositis-related complications develop. Immunosuppression with methotrexate, tacrolimus or leflunomide may be useful for the treatment of myositis with weakness. In some patients, the use of tacrolimus may result in a clinical improvement while awaiting a biologic response. In patients with pulmonary disease, treatment with corticosteroid alone is usually not efficacious, and corticosteroid therapy combined with anti-myositis medication is effective. If corticosteroid is ineffective, statins may delay progression of pulmonary disease and myositis.
The signs of myositis/inclusion body are very different. Patients with myositis tend to be more likely to experience weakness in the face, neck and shoulder, while patients with inclusion bodys tend to experience more intense muscle tenderness and greater swelling.
Myositis is the most common manifestation of inclusion body myositis. Although it manifests as a myopathy in many different ways, myositis is almost always a manifestation of inclusion body myositis, with an incidence of up to 91% in these cases. Even with this high incidence of myositis, the disease is still one of few that can rarely be diagnosed as a presentation of inclusion body myositis without the finding and/or confirmation of inclusion bodies in the skeletal muscle biopsy. Inclusion body myositis is diagnosed solely on the basis of histologic features. On skeletal muscle biopsy, there are few if any other diseases that are commonly misdiagnosed with inclusion bodies.
myositis-inclusion body, inclusion body, is a myopathy that occurs with marked muscle weakness, wasting or atrophy with a wide spectrum of clinical features. An important feature of inclusion body is weakness of the eye-lids, which appears as a fluttering ptosis or lid retraction or both in about half of all cases.
There was no evidence found of a significant change in clinical data for patients treated for one year with glucocorticoids. Nevertheless, clinical improvement or cure could not be proven, either in the short or in the long term.
This report provides preliminary evidence that antibodies against Ro/RS-SSA (or one of its autoantigens) and Scl can cause a primary form of myositis, as well as a secondary form.
There have been few other clinical trials in the UK that have investigated the use of methotrexate in the treatment of scleroderma. There is an ongoing study at [University of Southampton|University of Southampton]] for which participants have been recruited on a volunteer basis. Data from a recent study from this trial should be informative about which drugs might be effective in the future. If you want to find clinical trials in general, you can use Power(http://www.withpower.com/clinical-trials).
Many new methods are used and researched to treat myositis, inclusion body, but the effects are still unknown. New research in myositis will continue to develop new effective methods.
There are currently no treatments to prevent the inclusion body myositis phenotype. Treatments focus on treating symptoms. For example, [pain management](https://www.withpower.com/clinical-trials/pain-management) is paramount in the management of myositis. Most treatments that are prescribed are for pain, fatigue, or muscle weakness/tenderness. Exercise is an effective method to treat fatigue and muscle pain. Although myositis will occur and become progressively worse at the same intensity of exercise, some patients may experience reduced exercise intensity or fatigue associated with the exercise. This is related to the reduced sympathetic nervous system activity of the myositis, resulting in reduced metabolism and decreased energy needs. Exercise should be avoided during recovery and if tolerated, exercise should be increased progressively.
There is a significant family history of myositis, inclusion body in North Indian families. We concluded that it is not myositis, inclusion body run in families, but a single gene mutation which probably affects mitochondria.
There does not currently have a proven way to prevent either a case of rheumatoid myositis or muscle damage. However, there are currently a lot of different treatments prescribed to help with these conditions, and [information on non-curative treatments is available here(http://www.curesearch.ca/info/curative_treatments.html). The best way to determine whether the treatment is more effective and safer than a placebo is try out the treatment first and make a decision based on the benefits reported.